Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.

@article{Henry2015ExploringTP,
  title={Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.},
  author={Robert R. Henry and Julio Rosenstock and Steven V. Edelman and Sunder Raj D Mudaliar and Alexandros-Georgios Chalamandaris and Sreeneeranj Kasichayanula and Allyson Bogle and Nayyar Iqbal and J. F. Van Der List and Steven C. Griffen},
  journal={Diabetes care},
  year={2015},
  volume={38 3},
  pages={412-9}
}
OBJECTIVE Insulin adjustments to maintain glycemic control in individuals with type 1 diabetes often lead to wide glucose fluctuations, hypoglycemia, and increased body weight. Dapagliflozin, an insulin-independent sodium-glucose cotransporter 2 (SGLT2) inhibitor, increases glucosuria and reduces hyperglycemia in individuals with type 2 diabetes. The primary objective of this study was to assess short-term safety of dapagliflozin in combination with insulin; secondary objectives included… CONTINUE READING